Zobrazeno 1 - 10
of 34
pro vyhledávání: '"James C. Norton"'
Publikováno v:
Journal of Parkinson's Disease
Background: Parkinson’s disease psychosis (PDP) is a common nonmotor symptom that affects up to 60% of patients. Pimavanserin, a selective 5-HT2A inverse agonist/antagonist, is approved for treating hallucinations and delusions associated with PDP.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eb1e25e11be37e8e2f0a08882201fa0c
https://doi.org/10.3233/jpd-202047
https://doi.org/10.3233/jpd-202047
Publikováno v:
Clinical Nurse Specialist. 34:63-69
Purpose/objectives The hCATS (health Colleges Advancing Team Skills) to CPR (Cultivating Practices for Resilience) Camp was an interprofessional pilot program to promote resilience, introduce strategies for coping with stress, cultivate compassion, a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b8276796ddd478bb1a953259100f5464
https://doi.org/10.1097/nur.0000000000000506
https://doi.org/10.1097/nur.0000000000000506
Autor:
James C. Norton
Publikováno v:
Handbook of Psychology and Health ISBN: 9781003161530
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c251b9f8a6f484afb56af3922fc0f080
https://doi.org/10.4324/9781003161530-1
https://doi.org/10.4324/9781003161530-1
Autor:
Victor Abler, Marc Cantillon, Jason L. Aldred, Lori Jacobi, Gustavo Alva, James C. Norton, Daryl DeKarske, Rene Nunez, Bruce Coate
Publikováno v:
Journal of Parkinson's Disease
Background: Many patients with Parkinson’s disease (PD) experience depression. Objective: Evaluate pimavanserin treatment for depression in patients with PD. Methods: Pimavanserin was administered as monotherapy or adjunctive therapy to a selective
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7bde8bb7f1da2492cfaadc2f244aabb1
https://pubmed.ncbi.nlm.nih.gov/32804101
https://pubmed.ncbi.nlm.nih.gov/32804101
Autor:
Hubert H. Fernandez, Tihomir V. Ilić, James C. Norton, David L Kreitzman, Srdjan Stankovic, Jean-Philippe Azulay, Stuart Isaacson, Clive Ballard, Bruce Coate, Victor Abler, Joaquim J. Ferreira
Publikováno v:
Repositório Científico de Acesso Aberto de Portugal
Repositório Científico de Acesso Aberto de Portugal (RCAAP)
instacron:RCAAP
Repositório Científico de Acesso Aberto de Portugal (RCAAP)
instacron:RCAAP
© 2021 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license.
Introduction: Pimavanserin, a selective 5-HT2A inverse agonist/antagonist, was approved for hallucinations and delusions associated w
Introduction: Pimavanserin, a selective 5-HT2A inverse agonist/antagonist, was approved for hallucinations and delusions associated w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b3e9bd59836a830420547e27197b6fc6
https://pubmed.ncbi.nlm.nih.gov/33933853
https://pubmed.ncbi.nlm.nih.gov/33933853
Autor:
Stuart Isaacson, Srdjan Stankovic, Tihomir V. Ilić, George Demos, David L Kreitzman, Jean-Philippe Azulay, Hubert H. Fernandez, I-Yuan Liu, James C. Norton, Clive Ballard, Joaquim J. Ferreira, Victor Abler
Publikováno v:
Parkinsonismrelated disorders. 77
Introduction Pimavanserin is a selective 5-HT2A inverse agonist/antagonist approved for treating hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Results from short-term, placebo-controlled studies demonstrated a posi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5ecc69e48edbd26f79f9f3d1bb0292fa
https://pubmed.ncbi.nlm.nih.gov/32712560
https://pubmed.ncbi.nlm.nih.gov/32712560
Autor:
Doral Fredericks, Clive Ballard, Alberto J. Espay, Candace Andersson, Michael T. Guskey, Bruce Coate, Stewart A. Factor, Niccole J. Larsen, James C. Norton, Joseph H. Friedman, Joaquin A. Vizcarra, Daniel Weintraub, Anthony E. Lang
Publikováno v:
Movement Disorders. 33:1769-1776
Background: PD psychosis is often associated with cognitive impairment, including dementia, and involves dopaminergic, serotonergic, and cholinergic mechanisms. Objective: To evaluate the differential effect of the antipsychotic pimavanserin, a selec
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1d8d89cb1305a4edd030d0b54ab0001b
https://doi.org/10.1002/mds.27488
https://doi.org/10.1002/mds.27488
Publikováno v:
CNS Spectrums. 23:228-238
ObjectiveOur aim was to describe the efficacy and tolerability of pimavanserin, a highly selective serotonin 5-HT2A receptor inverse agonist/antagonist indicated for the treatment of hallucinations and delusions associated with Parkinson’s disease
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9b2f66fa9f60b6bd915cbe204deeafb0
https://doi.org/10.1017/s1092852917000736
https://doi.org/10.1017/s1092852917000736
Autor:
Marc Cantillon, Jason L. Aldred, James C. Norton, Michael T. Guskey, Bruce Coate, Gustavo Alva, Daryl DeKarske
Publikováno v:
CNS Spectrums. 25:301-301
Study Objectives:Depression occurs in ~50% of Parkinson’s disease (PD) patients, increases in severity and duration as the disease progresses, and is associated with increased morbidity. Improvement of depression in PD patients is correlated with r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::42fd9c26197311cd43c783f8b42e4a5a
https://doi.org/10.1017/s1092852920000747
https://doi.org/10.1017/s1092852920000747
Autor:
Pierre N. Tariot, James C. Norton, Jeffrey L. Cummings, James M. Youakim, Srdjan Stankovic, Clive Ballard, Erin P. Foff, Randy Owen
Publikováno v:
The Journal of Prevention of Alzheimer's Disease
Psychosis is common across dementia types with a prevalence of 20% to 70%. Currently, no pharmacologic treatment is approved for dementia-related psychosis. Atypical antipsychotics are frequently used to treat these disorders, despite significant saf
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::045b579111423f768230ae80cbfa1ba5
https://pubmed.ncbi.nlm.nih.gov/30298184
https://pubmed.ncbi.nlm.nih.gov/30298184